New medical technologies at startups in December 2015

Listed below are the technologies under development at medical technology startups identified in December 2015 and added to the Medtech Startups Database.

  • 3D-printed, patient-specific implants
  • Therapeutic temperature management.
  • Vessel preparation angioplasty balloon.
  • Control system for minimally invasive surgical tools.
  • Surgical solutions focused on robotic and other technology.
  • Undisclosed products, but based on brain-gut pathway; principals with background in diabetes, endocrinology.
  • Robotically-assisted minimal access surgery.
  • Novel catheter device as a treatment for heart failure with preserved ejection fraction.

For a historical listing of medtech startups identified by month, see link.

Wound Care Technologies: Sales Growth, Change, Global Forecast

MedMarket Diligence is hours away from publishing its 2015 report on the worldwide wound management market.

The report is entitled, “Worldwide Wound Management, Forecast to 2024: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”. The report is described in detail at link.

The very diverse field that is wound management encompasses technologies from gauze to bioengineered skin and skin substitutes and many in between. Growth rates range from flat to over 15% annually through 2024.

Source: MedMarket Diligence, LLC; Report #S251.

The highest growth segments in medical technology sectors typically derive their high growth from modest absolute changes on very small volume and therefore rarely can sustain that growth over time. However, in wound management, the use of bioengineered skin and skin substitutes will result in the highest cumulative sales compared to all segments from 2015 to 2024 — excluding, that is, the high volume segments of traditional adhesives, gauzes, and non-adherent dressings.  Also noteworthy is the second highest cumulative sales over this period was for antimicrobial dressings, despite this segment having relatively modest growth on a percentage basis, but proceeding from significant sales in 2015 (already at over $1.5 billion).

Source: MedMarket Diligence, LLC; Report #S251.

During the forecast period, the most significant change evident in sales is the jump in the share of the market represented by bioengineered and other skin replacements, as noted above. But with compound annual growth rates (to 2024) in sales in the different wound segments ranging from near 1% to nearly 20% — for segments with 2015 sales at a low of $300 million and a high of $15 billion — there is considerable shifting of shares of the global wound market.

Source: MedMarket Diligence, LLC; Report #S251.

On a geographic basis, wound care technology migration, efforts to secure underserved patient caseload, and other forces result in growth rates that vary by country or region. The well-developed USA market therefore does not compare in uptake of both old and new technologies within growth markets like China and others in the Asia/Pacific region.

Source: MedMarket Diligence, LLC; Report #S251.

Medtech Fundings for December 2015

Fundings in medical technology for December 2015 stand at $360.4 million, led by Spectranetics’ $110 million debt funding, followed by the $44 million launch funding of Kallyope, the $40 million funding of NxThera, and the $38.5 million funding of Axonics Modulation Technologies.

Below are the top fundings for the month, thus far. Please revisit this post (and refresh your browser) during December to see new medtech fundings.

For the complete list of fundings, see link.

For a month-by-month, historical list of fundings since 2009, see link.

Wound management: Novel technologies, high growth, high volume, MANY companies

Wound management technologies span an incredible spectrum of technologies — bandages, tapes, dressings (bioactive, antimicrobial, non-adherent…), sutures, staples, bioengineered skin & substitutes, negative pressure, ultrasound, pulsed electromagnetic therapy, growth factors, gene therapy…

Wound management is an old medical practice, and wounds have not changed in nature other than the mix prevalence of different wound types. Yet, the volume of all wounds, and the need to improve they may be managed, support development of many new technology and changes in clinical practice. In turn, this drives and sustains an unusually large number of competitors.

Source: MedMarket Diligence, LLC; Report #S251.

 

Below is a list, drawn from the forthcoming December 2015 report (#S251) from MedMarket Diligence global wound management market, of companies that are sufficiently large or active or noteworthy for us to have specifically profiled in our report. The true number of companies in wound (and detailed but not “profiled” in our report) is in the hundreds.

3M Health Care, ACell, Acelity L.P. Inc., AcryMed Inc., Agennix Incorporated, AGT Sciences Ltd, Alliqua Biomedical, AlloSource, Altrika Ltd, Amniox Medical, Inc., Anika Therapeutics, Argentum Medical, Avita Medical, B. Braun Melsungen AG, Biopharm GmbH, Biotime, Inc., Bio-Tissue, Inc., BSN medical, Cardium Therapeutics, CliniMed Limited, Coloplast Group, Covalon Technologies, Ltd., ConvaTec Inc., Cook Biotech, Inc., Covidien, Cytogenix, Cytomedix, Derma Sciences, Inc., DeRoyal Industries Inc., Devon Medical, Diapulse Corporation of America, Eqalix, Inc., E-QURE Corporation, Euroderm AG, Gentell Inc, Geritrex Corp., Hartmann Group, Hollister Incorporated, Imbed Biosciences, Inc., Integra LifeSciences, Inc., Kendall (Covidien), Kinetic Concepts, Inc. (KCI), Kuros Biosurgery AG, Laboratoires URGO, LifeCell Corporation, Lohmann & Rauscher International GmbH and Co. KG, Macrocure, Medline Industries, Microban International Ltd., MicroVas Technologies, Inc, MiMedx, Mölnlycke Health Care AB, NovaBay Pharmaceuticals, Oculus Innovative Sciences, Organogenesis Inc, Osiris Therapeutics, Perry Baromedical, Prospera, ReliaMed, RXi Pharmaceuticals, SafeBlood Technologies, Sanofi Biosurgery (formerly Genzyme Biosurgery), SANUWAVE Health, Inc., Shire Regenerative Medicine, Smith & Nephew plc, Sorbion GmbH & Co., KG, Soluble Solutions, LLC, Spiracur, Inc., Systagenix Wound Management (US), Inc., TEI Biosciences, Tissue Regeneration Technologies, LLC, Tissue Regenix Group plc., UDL Laboratories, Uluru, Inc., ViroMed Co., Ltd., Vomaris Innovations, Inc., Wound Management Technologies, Inc.

The MedMarket Diligence Report #S251, “Worldwide Wound Management, Forecast to 2024:
Established and Emerging Products, Technologies and Markets
in the Americas, Europe, Asia/Pacific and Rest of World” (see link for details), provides a current and forecast assessment (to 2024) of the worldwide market for wound management.

 

Acute Stroke Therapeutics and a $1.7+ Billion Neurointerventional Worldwide Market; MMD Report

Stroke is a costly condition with a growing patient population targeted neurointerventional treatments that will account for hundreds of millions in sales over the next five years, according to a recent MedMarket Diligence report.

Acute stroke therapeutics are focused almost exclusively on patients’ cardiopulmonary and hemodynamic support and ad hoc containment of dangerous complications and corresponding brain damage associated with stroke. Among the life-threatening complications that commonly accompany acute cerebral hemorrhage or ischemia are cerebral edema; hydrocephalus; brain stem compression; vasospasm and pulmonary embolism. These therapeutic technologies will account for $323 million in new revenue from 2015 to 2019, according to the recently published MedMarket Diligence report, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019”, details

“Stroke is associated with costly long-term care, especially for a patient population that is typically older and more susceptible to its complications, but neurointerventional treatment have succeeded in both making a positive clinical impact and securing respectable revenue streams for manufacturers,” says Patrick Driscoll of MedMarket Diligence. These technologies will continue to develop and improve over the next five years, but much growth will also come from the penetration by these technologies in non-U.S. markets, where relative use is lower and shows untapped potential.

Stroke is a life-threatening medical condition characterized by a sudden catastrophic breakdown in the brain-supporting cerebrovascular system and blood supply, which, in many instances, is followed by an irreversible injury to the brain cells and severe neurological impairment or death.

Notwithstanding the remarkable progress in medical science and technology and associated improvements in clinical practices, stroke continues to constitute the major public health problem in the U.S. and overseas.

The $1.5 billion global market for acute stroke management is revealed in detail in the MedMarket Diligence report #C310, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019”, (see http://mediligence.com/rpt/rpt-c310.htm). The report is a detailed market and technology assessment and forecast of the products and technologies in the management of acute stroke. The report describes the epidemiology, etiology and management of hemorrhagic stroke, ischemic stroke, subarachnoid hemorrhage, and transient ischemic attack, characterizing the patient populations, their current clinical management, and trends in clinical management as new techniques and technologies are expected to be developed and emerge. The report details the currently available products and technologies, and the manufacturers offering them. The report details the products and technologies under development and markets for each in the treatment of acute stroke. The report provides a current and forecast to 2019 by region /country for the U.S., Western Europe, the major Asia-Pacific states (China, India, and Japan), and the rest of world. The report profiles the most top companies in this industry, providing status and forecast data on their current products, current market position, and products under development.

The report is described in detail at http://mediligence.com/rpt/rpt-c310.htm and may be ordered for immediate download from https://www.mediligence.com/store/page54.html.

 

Spine Surgery Advances and Geographic Expansion Driving $9 Billion Market; MedMarket Diligence, LLC

Spine surgery manufacturers are driving growth by continuing to advance new technologies in implants, instrumentation and minimally invasive delivery while penetrating and expanding markets outside the U.S.

The $9.17 billion global market for cervical fusion, thoracolumbar Implants, MIS spine fusion, interbody fusion, and orthobiologics has evolved dramatically over the last several decades as a result of significant advances in the understanding of spinal biomechanics, the proliferation of sophisticated spinal instrumentation devices, surgical advances in bone fusion techniques, refinement of anterior approaches to the spine and the emergence and development of microsurgical, minimally invasive methods and robotics. As a result of these advances, it is now possible to stabilize every segment of the spine successfully, regardless of the offending pathology. The global market for spine surgery devices is detailed in the MedMarket Diligence report, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021.” (see http://www.mediligence.com/rpt/rpt-m540.htm)

“Well established and emerging spine surgery companies alike are succeeding by accomplishing three things — providing greater resources to further product development, expanding of sales and marketing resources, and growing new and emerging geographic regions,” says Patrick Driscoll, of MedMarket Diligence. “The result is continued strong sales growth globally, with a robust competitive landscape of companies of all sizes, keeping big players like Medtronic, DePuy,, Stryker, and Zimmer-Biomet on their toes” says Driscoll.

Spine fusion is the fastest growing technology in spine surgery and with growth in spine surgery being fastest in the Asia-Pacific and Central/Latin America, the growth of spine fusion in those areas is double-digit. The improvements in spine surgery and technology development have produced steady growth in volumes of surgeries, supported by reimbursement and clinical outcomes (and the increasingly active aging population). Spine surgery, with its exponential growth, has been the answer to an orthopaedic industry seeking to optimize earnings and add value for shareholders.

The MedMarket Diligence report, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World,” (report #M540) is a detailed market and technology assessment and forecast of the products and technologies in the management of diseases and disorders of the spine. The report describes the diseases and disorders of the spine, characterizing the patient populations, their current clinical management, and trends in clinical management as new techniques and technologies are expected to be developed and emerge.

The report details the currently available products and technologies, and the manufacturers offering them. The report details the products and technologies under development and markets for each in spine surgery. The report provides a current and forecast assessment by region/country of procedures and manufacturer revenues for, specifically, Americas (United States, Rest of North America, Latin America), European Union (United Kingdom, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (Japan, China, India, Rest of Asia/Pacific) and Rest of World. The forecast addresses the product- and country-specific impacts in the market of new technologies through the coming decade.

The report profiles 38 of the most notable current and emerging companies in this industry, providing data on their current products, current market position and products under development. The products and activities of numerous additional startup and emerging companies are also detailed in the report.

The report is described in detail at http://www.mediligence.com/rpt/rpt-m540.htm and may be ordered for immediate download from https://www.mediligence.com/store/page51.html.

Three Key Forces Behind Startups and Investment in Medical Technology

We see three key forces underlying investment trends in medical technology:

  • The spectrum of competition has been broadened and sometimes isn’t even obvious.

Widely different technologies (as in treatment of coronary artery disease, see white paper) can address a clinical condition, with the solution to the problem being the focus of new investment.

New materials for devices, drug-device hybrids, biotech-driven solutions, and other innovations can create competition between very different technologies. As a result, the paradigms and truths that held true in the past, when devices only went head-to-head with devices, are no longer relevant, creating the need to better assess the competitive landscape.

Manufacturers must there develop good market awareness, as in being cognizant of all the potential source of competition, such as from companies in adjacent markets who might pivot and seize market share.

  • Money flows to niches in medtech where the demand for clinical utility is high.

The biggest forces driving medtech are increasing patient populations or the cost of managing them. Niches that address the challenges of an older population with unsolved painful and or costly conditions (orthopedics, chronic wounds, diabetes, bariatrics) have prominent cost targets that stimulate investment.

Patient demographics, healthcare cost/utility demands and other forces make some medtech niches very attractive, even if only as a result of technology migration (e.g., to growth geo markets).

  • Underserved patient populations command almost as much attention as the untapped patient populations.

There is much potential return on investment to be made in blockbuster treatments, but these can be financial sinkholes compared to less grandiose technology solutions. A motive force exists in medtech, centered around healthcare costs, that is relentlessly forcing medical technology innovators to find opportunity within existing markets, by eliminating cost (e.g., shifting care to outpatient as via minimally invasive technologies). Significant medical technology investment has already recognized the value in targeting conditions for which new technology, new clinical practices and/or simply new ways of thinking can improve the quality of life, patient costs or both.

Medtech investment is most serious when it is (1) in high dollar value, or (2) tied to the formation of companies. It reflects confidence in that sector to the degree set by the investment.

In the past five years, MedMarket Diligence has tracked the identification of over 600 companies in medtech. Below is the distribution of their focus across a large number of clinical and technology areas (multiple possible, as in “minimally invasive” and “orthomusculoskeletal”).

These companies have also been tracked through their specific investments (detailed historically at link).

Source: MedMarket Diligence, LLC; Medtech Startups Database.

Cardiology, orthopedics, and surgery are mainstay drivers of new technology development in medtech, as has been the push for minimally invasive therapies, but nanotechnology, interventional (e.g., transcatheter) technologies, biomaterials, wound management and other niches have a steady stream of new company formations.


See recent reports from MedMarket Diligence in the following clinical areas.

Medtech Startups Database

2015startupsAs part of the effort of identifying and tracking the opportunities on the horizon in medical technology, MedMarket Diligence maintains a database of medical technology startup companies, the Medtech Startups Database.

Every month, we identify upwards of 20 companies who are less than two years old, most under one year old (and some only weeks old).

See link for detail on the current distribution of startups by clinical/technology area, country, and (for U.S.) state.

 

 

 

Active Companies in Spine Surgery, 2015

Companies covered in the MedMarket Diligence report #M540, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”.

  • A-Spine Holding Group Corp
  • A-Spine USA, Inc.
  • Aap Implantate AG
  • Aesculap AG & CO. KG
  • Alphatec Spine, Inc.
  • Anatomica AB
  • Argomedical GmbH
  • ARTOSS GmbH
  • Arthrex, Inc.
  • Biocomposites Ltd.
  • Biomatlante
  • Biomet, Inc.
  • Biomet Europe
  • Biomet UK Ltd
  • Biomet France S.A.R.L.
  • Biomet Italia S.r.l.
  • Biomet Deutschland GmbH
  • Biomet Spain Orthopaedics, S.L.
  • Biotechni
  • BONESUPPORT AB
  • Ceraver
  • coLigne AG
  • Corin Group PLC
  • Cousin Biotech
  • Curasan AG
  • DePuy Orthopaedics, Inc.
  • DePuy France
  • DePuy Orthopädie GmbH
  • DePuy Italy SRL
  • DePuy Spain c/o Johnson & Johnson Medical
  • DePuy UK
  • Dieter Marquardt Medizintechnik GmbH
  • Eden Spine Europe SA
  • Elos Medical AB
  • Exactech Inc.
  • Graftys
  • Groupe Lepine
  • HiT Medica
  • Hipokrat Medical Devices
  • Implants Industrie
  • Implants International
  • Implants International Limited
  • Integra Lifesciences
  • JRI Limited
  • K2M, Inc.
  • Kasios
  • Kiscomedica
  • Lafitt S.A.
  • LDR Médical
  • Lima LTO
  • Mathys AG Bettlach
  • Medicrea Technologies
  • Medtronic Spinal and Biologics
  • Medtronic Österreich GmbH
  • N.V. Medtronic Belgium S.A.
  • Medtronic GmbH
  • Medtronic France S.A.S.
  • Medtronic Ibérica, S.A.
  • Medtronic Italia S.p.A.
  • Medtronic Limited
  • Orthovita, Inc.
  • OSD – Orthopaedic & Spine Development
  • Peter Brehm GmbH
  • Permedica S.p.A.
  • PINA Medizintechnik Vertriebs AG
  • Serf
  • SIGNUS Medizintechnik GmbH
  • Sintea Biotech S.p.A.
  • Small Bone Innovations, Inc.
  • Small Bone Innovations International
  • Smith & Nephew plc
  • Smith & Nephew Inc
  • Smith & Nephew SA
  • Smith & Nephew GmbH
  • Smith & Nephew S.A.
  • Smith & Nephew Orthopaedics Ltd
  • Spine Network
  • SpineVision SA
  • Stryker Corporation
  • Stryker European Headquarters
  • Stryker France SA
  • Stryker Howmedica GmbH
  • Stryker UK Limited
  • Stryker Italia S.r.l.
  • Stryker Howmedica Iberica S.L.U.
  • Surgi C
  • SURGIVAL-GRUPO COSíAS
  • Surgicraft
  • Synimed Synergie Ingénierie Médicale S.A.R.L.
  • Synthes GmbH
  • Teknimed
  • Vertebron
  • Viscogliosi Brothers LLC
  • Tornier S.A.
  • Wright Medical Technologies Inc
  • Zimmer Holdings Inc.
  • Zimmer France
  • Zimmer Chirurgie GmbH
  • Zimmer S.R.L., Italy
  • Zimmer, S.A.
  • Zimmer Ltd

See, ” MedMarket Diligence report #M540, “Global Market for Medical Device Technologies in Spine Surgery, 2014-2021”. Published September 2015.

Technologies in Development at Medtech Startups, October 2015

In our flurry of activity in October, we overlooked summarizing the new medical technologies identified at startups and added to the Medtech Startups Database:

  • Neodymium vaginal dilator for treatment of pelvic pain.
  • Large bore, power injection vascular access
  • Surgical instruments for use in bariatrics.
  • Surgical oncology.
  • Spine surgical technology including expandable intervertebral cage.
  • Technologies to treat hearing loss.
  • Device to determine blood vessel size.
  • Cerebrospinal fluid shunt.
  • Focused ultrasonic surgical devices for hemostasis, cauterization, and ablation.
  • Collagen polymers to create 3D tissue systems for drug discovery, engineered tissue/organ, wound management, and 3D bioprinting.
  • Regenerative medicine to treat brain injury or damage.
  • Neuro-monitoring and neuro-critical care.
  • Orthomusculoskeletal implants.
  • Devices and methods for hip replacement
  • Intraoperative image system.
  • Exocentric medical device
  • Electro-hydraulic generated shockwave for cosmetic, medical applications.

For a historical listing of technologies at medtech startups, see link.